Basic Dilantin Information

• INN (International Nonproprietary Name): Phenytoin.
• Brand Names Available In Canada (English): Dilantin, Dilantin-30, Dilantin-125, Dilantin Infatabs.
• ATC Code: N03AB02.
• Forms & Dosages: Capsules (30 mg, 100 mg), chewable tablets (50 mg, 100 mg), oral suspension (125 mg/5 mL), injectable solution (50 mg/mL ampoules in 2 mL or 5 mL).
• Manufacturers In Canada (English): Pfizer Canada is the named supplier; generics available from international manufacturers are imported and sold under DINs.
• Registration Status In Canada (English): Registered with Health Canada for seizure indications and listed as prescription-only (Rx).
• OTC / Rx Classification: Prescription only.

Key Findings From Recent Trials

Major 2022–2025 Canadian & Global Studies

Patients and clinicians have asked whether new randomized trials have changed how we use dilantin.

The strongest evidence from 2022 to 2025 comes from observational cohorts, pharmacokinetic studies, and registry analyses rather than large new RCTs.

Canadian pharmacokinetic work focused on older adults and variability between total and free phenytoin levels.

International pregnancy registries continued to collect data showing teratogenic risk linked to phenytoin exposure in pregnancy.

Trend analyses show reduced first-line prescribing of phenytoin for new-onset focal or generalized tonic‑clonic epilepsy in favour of levetiracetam and lamotrigine.

Phenytoin still holds a role in acute settings, particularly for status epilepticus when intravenous formulations or fosphenytoin are used.

The literature and registry reports from 2023–2025 referenced in these summaries highlight the practical role of phenytoin without overturning existing indications.

Main Outcomes

Observational data emphasise pharmacokinetic variability, especially in older patients and those with low albumin.

Registries documented persistent seizure‑control benefits for patients already established on phenytoin.

Comparative prescribing studies recorded a steady decline in first‑line use for new diagnoses compared with alternatives such as levetiracetam.

In hospital protocols for status epilepticus, intravenous phenytoin or fosphenytoin remains a second‑line option after benzodiazepines in many centres.

Safety Observations

Post‑market safety analyses from 2022–2025 reinforced known safety issues rather than identifying new, widespread harms.

Key safety themes included enzyme induction leading to clinically relevant drug interactions and the need for routine monitoring of liver enzymes and blood counts.

Reports from pregnancy registries reiterated teratogenic risk, prompting careful risk–benefit counselling for women of childbearing potential.

Adverse events such as gingival hyperplasia, skin reactions, and blood dyscrasias continued to appear in pharmacovigilance reports.

Clinical Mechanism Of Action

Layman’s Explanation

People often ask how dilantin actually stops seizures.

Phenytoin calms overactive nerve cells by preventing rapid, repeated firing of electrical signals in the brain.

The medicine does this by stabilizing sodium channels in nerve membranes so that bursts of abnormal activity are less likely to spread.

That dampening effect reduces the chance of a seizure starting or generalizing across the brain.

Scientific Breakdown

Phenytoin produces a state‑ and use‑dependent block of voltage‑gated sodium channels (Nav), favouring rapidly firing neurons.

This preferential binding prolongs the inactivated state of Nav channels and reduces repetitive high‑frequency discharge that underlies many seizures.

Indirect effects include decreased presynaptic glutamate release, which further limits excitatory transmission.

Hepatic metabolism is primarily via CYP2C9 and CYP2C19 and exhibits nonlinear (saturable) kinetics at higher concentrations.

Because of nonlinear pharmacokinetics, small dose increases can cause disproportionately large rises in plasma concentrations.

Typical therapeutic total plasma concentrations are approximately 10–20 mcg/mL, with free (unbound) monitoring recommended in hypoalbuminaemia or renal impairment.

Available formulations include 30 mg and 100 mg capsules, chewable tablets, and a 125 mg/5 mL suspension per product monographs.

Scope Of Approved & Off-Label Use

Health Canada Approvals (DIN-Based)

Health Canada approves phenytoin formulations for tonic‑clonic and focal seizures and for prophylaxis following neurosurgery or head trauma, with products carrying DINs.

Commercial Canadian labels include Dilantin, Dilantin-30, Dilantin-125 and Dilantin Infatabs packaged as capsules, chewables and oral suspension.

Use is prescription‑only and product monographs define approved indications, dosing ranges and monitoring requirements.

Notable Off-Label Trends In Canadian Practice

In Canadian hospitals and some neurosurgical units, phenytoin is still used off‑label for short‑term post‑traumatic seizure prophylaxis in selected patients.

In refractory status epilepticus, clinicians sometimes choose intermittent IV phenytoin when fosphenytoin or other options are unavailable.

Primary care and neurology prefer agents with simpler pharmacokinetics and fewer interactions—such as levetiracetam—for routine initiation of chronic therapy.

Provincial formularies differ in coverage for generic phenytoin on public drug plans, and prior authorisation may apply in some provinces.

Dosage Strategy

General Dosing Per Health Canada Monographs

Adult oral dosing commonly begins at 100 mg three times daily with titration to clinical effect and serum concentrations.

Children usually start at about 5 mg/kg/day divided and maintenance commonly falls in the 4–8 mg/kg/day range.

Intravenous phenytoin (50 mg/mL ampoules) or fosphenytoin is used for acute seizure control with weight‑based loading in hospital settings.

Aim for total phenytoin concentrations of approximately 10–20 mcg/mL, adjusting based on free levels when indicated.

Condition-Specific Dosing Adjustments

Elderly patients frequently require lower doses due to reduced clearance and increased sensitivity to adverse effects.

Liver impairment requires dose reduction and closer level monitoring because phenytoin is hepatically metabolized.

In renal impairment, monitor free phenytoin to account for altered protein binding rather than relying solely on total concentrations.

Abrupt withdrawal should be avoided because it can precipitate status epilepticus or seizure recurrence.

When administering IV, follow slow infusion rates and cardiac monitoring guidance from the product monograph to reduce cardiovascular risks.

Safety Protocols

Contraindications (Canadian Advisories)

Absolute contraindications include known hypersensitivity to phenytoin or other hydantoins.

Co‑administration with delavirdine is contraindicated.

Severe hepatic impairment and certain cardiac conduction abnormalities require caution, especially with IV use.

Adverse Effects (Post-Market Reports)

Common adverse effects reported include drowsiness, dizziness, nystagmus, ataxia, tremor and gastrointestinal upset.

Gingival hyperplasia and cosmetic concerns are common among long‑term users and should be discussed during counselling.

More serious events reported in pharmacovigilance include severe cutaneous adverse reactions (SJS/TEN), blood dyscrasias and hepatotoxicity.

Phenytoin carries teratogenic risk and pregnancy requires specialist risk–benefit discussion and planning.

Monitoring protocols include baseline and periodic CBC, liver function tests and serum phenytoin levels, with free levels measured in hypoalbuminaemia.

For IV administration, monitor cardiovascular status and have resuscitation equipment available per hospital policy and the product monograph.

Adverse events in Canada should be reported through Canada Vigilance to support ongoing safety monitoring.

Interaction Mapping

Food Interactions Common In Canadian Diet

Patients ask whether what they eat affects phenytoin absorption and levels.

High‑fat meals can modify the absorption of some oral formulations, so advise consistent timing of doses in relation to meals.

Alcohol acutely enhances central nervous system depression and chronic alcohol use can alter phenytoin metabolism.

Drug Combinations Flagged By Health Canada

Phenytoin is a potent inducer of hepatic enzymes (CYP2C9, CYP2C19, CYP3A4), reducing plasma concentrations of many drugs.

Clinically important interactions include reduced efficacy of hormonal contraceptives, altered anticoagulant levels (warfarin and DOACs), and decreased exposure to certain antivirals and oncology agents.

Co‑prescription with carbamazepine or valproic acid involves complex interactions and requires careful monitoring.

Health Canada specifically flags delavirdine as contraindicated with phenytoin.

Pharmacists should lead medication reconciliation and therapeutic drug monitoring when starting or stopping interacting medicines.

Patient Experience Analysis

Canadian Survey Data

Surveys from 2022–2025 indicate that many long‑term phenytoin users appreciate reliable seizure control and the affordability of generic formulations.

Patients commonly report bothersome side effects such as cognitive slowing, gum changes and cosmetic issues related to gingival hyperplasia.

Adherence is sometimes challenging due to multiple daily doses and regular blood tests for monitoring.

Forum & Community Pharmacy Trends

Community pharmacists at major chains report frequent questions about brand versus generic products and concerns about cross‑border pricing differences.

Pharmacy counselling focuses on consistent dosing, interaction checks and coordination of therapeutic drug monitoring with lab services.

Provincial formulary listings and public coverage materially affect access and adherence for eligible patients.

Distribution & Pricing Landscape

National Pharmacy Chains

Major Canadian retailers such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs stock Dilantin and generic phenytoin formulations for community dispensing.

Hospital pharmacies maintain injectable ampoules (50 mg/mL) for acute care use under procurement and sterile compounding rules.

Online Pharmacy Availability & Provincial Restrictions

Licensed Canadian online pharmacies dispense phenytoin with a prescription, subject to provincial dispensing rules and DIN‑based reimbursement.

Provincial formularies like Ontario Drug Benefit, BC PharmaCare and RAMQ list generic phenytoin with varying eligibility and prior authorisation requirements.

In our online pharmacy, dilantin is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross-Border US Comparisons

List prices in the United States can appear lower, but insurance, rebates and regulatory differences affect real cost comparisons.

Importation of prescription drugs remains legally restricted and patients should use licensed Canadian pharmacies to ensure product quality and appropriate counselling.

Alternative Options

Comparison Table Of DIN-Approved Alternatives

When clinicians consider alternatives to phenytoin, common DIN‑approved options in Canada include carbamazepine, valproic acid, levetiracetam and lamotrigine.

Each alternative has a distinct profile for interactions, teratogenicity, tolerability and titration needs.

Pros And Cons Checklist

Levetiracetam: favourable pharmacokinetics and few interactions, but behavioural adverse effects are possible.

Lamotrigine: lower cognitive burden and mood benefits in some patients, but slow titration and rash risk require care.

Carbamazepine: effective for focal seizures, but strong enzyme induction and hyponatraemia risk are relevant.

Valproic acid: broad efficacy across seizure types, but significant teratogenic and metabolic risks limit use in women of childbearing potential.

For acute status epilepticus, hospital protocols generally prioritise benzodiazepines first, then fosphenytoin or phenytoin as second‑line options depending on availability.

Regulatory Status

Health Canada Approval Process

Health Canada approves medicinal products based on evidence of safety, efficacy and quality and assigns DINs for marketed formulations.

Phenytoin products in Canada are approved for seizure indications and remain prescription‑only with product monographs guiding use.

Health Canada and provincial authorities issue label updates or safety communications when new evidence emerges.

DIN And Bilingual Labelling Rules

Canadian labelling requires bilingual (English/French) patient information leaflets and product monographs for retail products sold in Canada.

Hospital purchasing and use of IV products follow provincial procurement policies and sterile compounding regulations.

Adverse reactions are reportable to Canada Vigilance as part of post‑market surveillance.

Consolidated FAQ

• Q: Is Dilantin covered by public drug plans in Canada? A: Some provincial plans list generic phenytoin; coverage and prior authorisation vary by province such as Ontario, BC and Quebec.
• Q: Can I buy Dilantin online from Canadian pharmacies? A: Licensed Canadian online pharmacies dispense phenytoin with a prescription; cross‑border importation is legally restricted.
• Q: What monitoring is required? A: Baseline and periodic CBC, liver function tests and serum phenytoin levels; free levels when hypoalbuminaemia is present.
• Q: Is phenytoin safe in pregnancy? A: Phenytoin has teratogenic risks; pregnancy requires specialist neurology and obstetrics discussion to weigh seizure control versus fetal risk.
• Q: How should I store Dilantin at home? A: Store at room temperature (20–25°C), protect from moisture and light, and keep out of reach of children.

Visual Guide

Patients often benefit from simple visuals that outline dosing, coverage and how to buy dilantin safely.

Suggested infographic 1: Dosage flowchart showing loading versus maintenance dosing and separate branches for adult and paediatric regimens and IV ampoule steps.

Suggested infographic 2: Provincial coverage map with icons for Ontario, British Columbia and Quebec indicating likely prior authorisation or listed status.

Suggested infographic 3: Purchase channels showing hospital (IV ampoules), retail chains (capsules and suspension), online pharmacies (prescription required) and a cross‑border caveat.

Suggested infographic 4: Monitoring timeline with baseline labs, checks 2–4 weeks after dose change, then periodic monitoring intervals.

Design notes: include bilingual captions, DIN callouts, and manufacturer logos where permitted, with clear colour coding for risk tiers.

Storage & Transport

Canadian Household Guidelines

Store phenytoin capsules, chewables and suspension at room temperature between 20–25°C and protect from excessive moisture and light.

Keep all medication in original packaging with the label and DIN for identification when travelling or presenting to healthcare providers.

Avoid leaving medication in vehicles or in direct sunlight where temperature extremes can occur.

Cold-Chain Storage Where Applicable

Injectable ampoules are managed by hospital pharmacies under institutional cold‑chain and sterile handling procedures and are not intended for patient transport.

Community patients should follow standard disposal advice for expired or unused medications and consult their pharmacist for safe disposal options.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Pharmacists advise taking phenytoin at consistent times each day and to inform prescribers before starting or stopping any other medication.

Pharmacist counselling should cover interaction risks with hormonal contraceptives and anticoagulants and emphasise the importance of therapeutic drug monitoring.

For women planning pregnancy, pharmacists should prompt referral to neurology and obstetrics for specialist counselling and alternative AED consideration when appropriate.

Provincial Health Authority Guidance

Provincial health authorities provide local acute‑seizure protocols where benzodiazepines are first‑line and fosphenytoin or phenytoin are second‑line choices under hospital algorithms.

Community care aligns treatment choices with formulary restrictions; pharmacists help with DIN verification and liaise with prescribers about prior authorisation requirements.

Follow the Health Canada product monograph and local hospital protocols for dosing, monitoring and IV administration precautions.

Delivery Across Canada (English)

Final Notes For Patients And Clinicians

If you are prescribed dilantin, expect a tailored plan for dosing and blood monitoring to balance seizure control and side effects.

Discuss contraception and pregnancy plans early with your clinician because phenytoin carries teratogenic risk.

Bring a complete medication list to each appointment so pharmacists and prescribers can check for interactions with warfarin, DOACs, hormonal contraceptives and other common drugs.

Ask your pharmacist about free phenytoin level testing if you have low albumin, renal impairment or an unexpected change in seizure control.

For acute seizures in hospital settings, protocols frequently include benzodiazepines first, and then fosphenytoin or phenytoin for loading doses as appropriate.

Report any rash, unexplained bruising, jaundice or severe dizziness to your healthcare team immediately and report adverse events to Canada Vigilance.